AHFS Drug Information

Try before you buy - Download the FREE App, which includes sample content.
An in-App purchase is required to unlock all content.

AHFS Drug Information succeeds in offering an updated drug compendium of evidence-based drug monographs, meeting the needs of todays healthcare professionals.
The reference continues to be trustworthy, relying on the most prestigious and knowledgeable drug experts in the medical field.

This reference can be used by any healthcare professional utilizing or prescribing medications in their practice, including physicians, pharmacists, physician assistants, and nurse practitioners.
The book is so nicely organized and easily referenced that it can also be used by students in the medical, pharmacy, and nursing fields as well.

(Melissa M.
Potts, BS, PharmD, Doodys Review Service, 2020)

AHFS is the only drug information resource with content developed by a professional editorial and analytical staff of pharmacists for a not-for-profit scientific organization and the only remaining original federal compendium whose authority for establishing accepted medical uses includes the broadest scope of drugs and indications under Medicaid, Medicare Part D, and more.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

2022 Updates Include:

Drug information for COVID-19 vaccines and COVID-19 monoclonal antibodies available under FDA Emergency Use Authorizations (EUAs), including clinical considerations from the US Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), and other authorities

Breakthroughs in oncology approved under the FDAs accelerated approval program

Expanded content on off-label uses, real-world data, and long-term clinical data

Information on patient selection and appropriate use of corticosteroids in the management of COVID-19 based on recent guidelines from NIH and the World Health Organization (WHO)

Contemporary issues such as anticoagulant reversal strategies and use of direct oral anticoagulants versus warfarin for treatment of venous thromboembolism or atrial fibrillation

Current best practices such as reversal of neuromuscular blocking agents for prevention of postoperative residual neuromuscular blockade

Updated information on pharmacogenomic considerations based on recommendations from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

Addition of 51 new molecular entities (NMEs) or new therapeutic biological products approved since January 2021

No internet connection is required to access the content after the initial download.
Find information quickly using powerful SmartSearch technology.
Search part of term for those hard to spell medical terms.

ISBN 10: 1585286842

ISBN 13: 9781585286843

SUBSCRIPTION :

Please purchase a yearly auto-renewing subscription to receive content access and available updates.

Yearly auto-renewing payments- $99.99

Payment will be charged to your iTunes Account at confirmation of purchase.
Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period.
Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device Settings and tapping iTunes & App Store.
Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.

If you have any questions or comments, email us any time: [email protected] or call 508-299-3000

Privacy Policy - https: //www.skyscape.com/terms-of-service/privacypolicy.aspx

Terms and Conditions - https: //www.skyscape.com/terms-of-service/licenseagreement.aspx

Editor-in-Chief: Elaine K.
Snow

Author(s): Gerald K.
McEvoy, Pharm.D

Publisher: American Society of Health-System Pharmacists,

Page navigation:

• < Prev
• Next >